An observational, safety follow-up extension to studies 2203 and 2203E1 to assess the safety of AAE581 in postmenopausal women with osteopenia/osteoporosis
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Balicatib (Primary)
- Indications Postmenopausal osteoporosis
- Focus Biomarker; Pharmacodynamics
- Sponsors Novartis
- 20 Nov 2013 New trial record